FEATURED ARTICLE

 

Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

PR Newswire  2018-05-17 04:10:00

DARMSTADT, Germany, May 17, 2018 /PRNewswire/ -- Not intended for UK- or US-based media ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase...

Full Story »

Comments

No Comments
Your name: *
Email:
Comment: *
 
Share
submit to reddit
Expedia